SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-1.47%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$323M
AUM Growth
+$323M
(-20%)
Cap. Flow
-$75.3M
Cap. Flow
% of AUM
-23.33%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
3
Closed
2
Top Buys
| 1 |
Lantheus
LNTH
|
$3.31M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$46.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
$13.8M |
| 3 |
Cytokinetics
CYTK
|
$13M |
| 4 |
Biogen
BIIB
|
$5.22M |
| 5 |
RGLS
Regulus Therapeutics
RGLS
|
$291K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Innoviva
INVA
$1.29B
| $126M | 39.11% | 7,277,000 | – | – |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $72.6M | 22.49% | 16,390,000 | – | – |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $42.2M | 13.07% | 309,116 -101,367 | -25% | -$13.8M |
|
|
4
Cytokinetics
CYTK
$4.23B
| $39.2M | 12.15% | 833,799 -276,201 | -25% | -$13M |
|
|
5
Gilead Sciences
GILD
$140B
| $24.2M | 7.5% | 262,080 -501,253 | -66% | -$46.3M |
|
|
AMRN
6
Amarin Corp
AMRN
$311M
| $12.1M | 3.73% | 24,850,623 | – | – |
|
|
7
Lantheus
LNTH
$3.73B
| $5.64M | 1.75% | 63,000 +37,000 | +142% | +$3.31M |
|
8
Vor Biopharma
VOR
$250M
| $686K | 0.21% | 618,000 | – | – |
|
|
9
Biogen
BIIB
$19.4B
| – | – | -26,950 | Closed | -$5.22M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| – | – | -185,183 | Closed | -$291K |
|